Cstone Pharmaceuticals Is An Innovation Driven Biopharmaceutical Company Founded In Late 2015 And Listed On The Hong Kong Stock Exchange Under The Ticker Symbol 2616The Company Specializes In Researching And Developing Anti Cancer Therapieswith A Strong Focus On Immuno Oncology And Precision Medicines To Meet Medical Needs In China And Globally Cstone Offers A Wide Range Of Services In Drug Developmentincluding Preclinical And Translational Researchclinical Developmentdrug Manufacturingbusiness Developmentand Commercializationthe Company Has A Robust Portfolio Of Approved Productssuch As Gavretopralsetinib Ayvakitavapritinib Cejemlysugemalimab And Tibsovoivosidenib Additionallycstone S Pipeline Includes 17 Innovative Assetsfeaturing Antibody Drug Conjugatesmultispecific Antibodiesimmunotherapiesand Precision Medicinesthe Experienced Management Team Ensures Effective Development And Marketing Of Its Products
